Human Gut Microbiome Metabolism of 12 Bioactive Coumarins via LC-MS/MS

12 structurally diverse bioactive coumarins were screened using semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces. The dataset, authored by Gabrielle Mingolelli and last updated in April 2026, explores how the gut microbiome reduces the α,β-unsaturated lactone of these compounds, a pathway involving 11 identified microbial species.

Use Cases

• Identify gut microbial species capable of metabolizing coumarins based on the monoculture screen of 11 isolates.
• Study the impact of microbial metabolism on drug cytotoxicity based on the diminished effect of methoxsalen metabolites on melanoma cells.
• Analyze the structural scope of the α,β-unsaturated lactone reduction pathway across different coumarin subclasses (isocoumarin, furano, pyrano, prenylated).

Strengths

• Focuses on a specific metabolic pathway (α,β-unsaturated lactone reduction) for a class of 12 bioactive compounds.
• Includes validation from a monoculture screen identifying 11 microbial species with the metabolic capability.
• Links microbial metabolism to a functional outcome, showing diminished cytotoxicity of a metabolite against cancer cells.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect bias inherent to the specific ex vivo fecal culture methodology used.

Provenance

Source

figshare

Collection Method

Semitargeted LC-MS/MS metabolomics and ex vivo cultures of human feces, followed by a monoculture screen of microbiome isolates.

Freshness

Last updated 2026-04-28 10:14:52; freshness should be verified.